Total Valuation
Daewoong Pharmaceutical Co., Ltd. has a market cap or net worth of ₩1.47T. The enterprise value is $2.70M.
Market Cap₩1.47T
Enterprise Value$2.70M
Share Statistics
Daewoong Pharmaceutical Co., Ltd. has 11,586,575 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,586,575
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Daewoong Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 9.52%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)9.52%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee909.60M
Profits Per Employee113.41M
Employee Count1,727
Asset Turnover0.66
Inventory Turnover2.44
Valuation Ratios
The current PE Ratio of Daewoong Pharmaceutical Co., Ltd. is 7.3. Daewoong Pharmaceutical Co., Ltd.’s PEG ratio is 0.01.
PE Ratio7.3
PS Ratio1.27
PB Ratio1.98
Price to Fair Value1.98
Price to FCF-47.17
Price to Operating Cash Flow9.05
PEG Ratio0.01
Income Statement
In the last 12 months, Daewoong Pharmaceutical Co., Ltd. had revenue of 1.57T and earned 195.86B in profits. Earnings per share was 17.02K.
Revenue1.57T
Gross Profit812.85B
Operating Income195.51B
Pretax Income191.83B
Net Income195.86B
EBITDA245.78B
Earnings Per Share (EPS)17.02K
Cash Flow
In the last 12 months, operating cash flow was 163.33B and capital expenditures -273.47B, giving a free cash flow of -110.13B billion.
Operating Cash Flow163.33B
Free Cash Flow-110.13B
Free Cash Flow per Share-9.51K
Dividends & Yields
Daewoong Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.17
52-Week Price Change-18.62%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Daewoong Pharmaceutical Co., Ltd. upcoming earnings date is Aug 18, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Daewoong Pharmaceutical Co., Ltd. as a current ratio of 1.24, with Debt / Equity ratio of 87.76%
Current Ratio1.24
Quick Ratio0.72
Debt to Market Cap0.41
Net Debt to EBITDA2.69
Interest Coverage Ratio15.67
Taxes
In the past 12 months, Daewoong Pharmaceutical Co., Ltd. has paid -1.08B in taxes.
Income Tax-1.08B
Effective Tax Rate>-0.01
Enterprise Valuation
Daewoong Pharmaceutical Co., Ltd. EV to EBITDA ratio is 10.81, with an EV/FCF ratio of -62.77.
EV to Sales1.69
EV to EBITDA10.81
EV to Free Cash Flow-62.77
EV to Operating Cash Flow17.81
Balance Sheet
Daewoong Pharmaceutical Co., Ltd. has ₩168.03B in cash and marketable securities with ₩900.43B in debt, giving a net cash position of -₩732.39B billion.
Cash & Marketable Securities₩168.03B
Total Debt₩900.43B
Net Cash-₩732.39B
Net Cash Per Share-₩63.21K
Tangible Book Value Per Share₩66.21K
Margins
Gross margin is 51.41%, with operating margin of 12.45%, and net profit margin of 12.47%.
Gross Margin51.41%
Operating Margin12.45%
Pretax Margin12.21%
Net Profit Margin12.47%
EBITDA Margin15.65%
EBIT Margin12.45%
Analyst Forecast
The average price target for Daewoong Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast10.31%
EPS Growth Forecast419.33%